Medical Decisions, Estrogen and Aging
Springer Science & Business Media, 20.12.2007 - 178 Seiten
If you are a woman between the ages of 45 and 75 and are trying to decide whether to try, or stick with, hormone therapy (HT), or if you are a physician with patients fitting this description, this book is for you – unless you are looking for a simple answer. If you are looking for a simple answer, you can go to the web site of one of the companies that manufactures hormones or makes money by administering hormone therapy (e. g. , AntiAgingGroup. com), or you can go to the we bsite of an organization that advocates ‘natural’ aging (e. g. , the Inter National Organization to Reclaim Menopause; Inorm. org). Any impartial advisor, however, is going to admit that the answer isn’t at all clear-cut. Jay Schulkin, I believe the reader will find, is such an impartial advisor, and he is going to take you several steps beyond simply acknowledging the ambiguity; he’s going to educate you about the biology, history, sociology, business, and ethics of hormone replacement therapy. As a prominent scientist doing research on hormones, a medical researcher, an expert on decision making, he is the ideal guide to the intricacies of the topic. You might think that all of this sounds superfluous for making an informed decision: “Just the facts, please.
Was andere dazu sagen - Rezension schreiben
Es wurden keine Rezensionen gefunden.
Andere Ausgaben - Alle anzeigen
advertising Alzheimer's disease associated Baron Barrett-Connor behavior bias biases Bioethics brain breast cancer Canadian Consensus cardiovascular clinical cognitive function colorectal cancer context coronary culture decision sciences decline decrease dementia depression Dewey diabetes diverse forms dose drug effects of estrogen effects of HT endometrial cancer enhance estradiol estrogenic compounds Ethics evidence evidence-based medicine fractures guidelines gynecologists Health Initiative heart disease Holzman hormone replacement therapy hormone therapy hot flashes increased risk issues JAMA Kahneman levels linked McEwen medical decision-making memory menopause mg/day CEE mood ObstetGynecol obstetrician obstetrician-gynecologists older women osteoporosis ovarian cancer patients perimenopausal pharmaceutical companies physicians physiological placebo postmenopausal women practice Premarin prescribing HT prescription progesterone progestin raloxifene randomized control trials regard to HT reported response risk factors risk of breast risks and benefits Rossouw Schulkin stroke symptoms tissue treatment vulnerability WHI studies women on HT Women’s Health
Seite 164 - Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.